- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The pharmacokinetics of ezetimibe are comparable in children and adults:
Resorption: rapid. Tmax = 1–2 hours (active metabolite), 4–12 hours (ezetimibe). Plasma protein binding: 88–92% (active metabolite), 99.7% (ezetimibe). Metabolization: glucuronidated in the liver to the active compound, ezetimibe glucuronide. Ezetimibe and its active metabolite undergo enterohepatic circulation. Elimination: approx. 78% in the faeces, primarily as ezetimibe and approx. 11% in the urine, primarily as the active metabolite. T½el = approx. 22 hours (ezetimibe, active metabolite).
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Primary hypercholesterolaemia, homozygous familial hypercholesterolaemia, homozygous sitosterolaemia (phytosterolaemia) |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
In a study in children (6 to 10 years) with heterozygous familial or non-familial hypercholesterolaemia (n = 138), increases in ALT and/or AST (≥ three times the upper normal value consecutively) were observed in 1.1% (1 patient) of patients taking ezetimibe compared to 0% of patients in the placebo group. No CPK elevations (≥ ten times the upper normal value) occurred. No cases of myopathy were reported. [SmPC Ezetrol 02/2021 GER]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Clinical experience in children and adolescents (ages 6 to 17 yrs) is limited to homozygous and heterozygous familial hypercholesterolaemia and sitosterolaemia. Treatment in children should be adjusted by a specialist doctor. The long-term effects on use for > 33 weeks have not been determined in children aged between 10 and 18 years and for > 12 weeks in children from 6-10 years.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| HMG CoA reductase inhibitors | ||
|---|---|---|
| C10AA05 | ||
| C10AA03 | ||
| C10AA07 | ||
| C10AA01 | ||
| Bile acid sequestrants | ||
|---|---|---|
| C10AC01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- MSD, SPC Ezetrol (RVG 28626) 05-02-2016, www.geneesmiddeleninformatiebank.nl
- Kusters D et al, Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia, J Pediatr., 2015, Jun;166(6), 1377-84
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
